Ampio Pharmaceuticals Inc Stock News

ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for common inflammatory conditions, today announced positive data from the modified Intent-to-Treat…

Baudax Bio, Inc. (NASDAQ:BXRX) with the stream of -2.56% also noticed, India Ampio Pharmaceuticals, Inc. (AMEX:AMPE) encountered a rapid change of 0.03% in the last hour of Thursdays trading session. The post Traders shouldnt Staggering on this: Baudax Bio, Inc. (NASDAQ:BXRX), Ampio Pharmaceuticals, Inc. (AMEX:AMPE) appeared first on Stocks Equity .

Zacks Investment Research lowered shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) from a buy rating to a hold rating in a report issued on Thursday morning, Zacks.com reports. According to Zacks, Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company []

ENGLEWOOD, Colo., Dec. 16, 2021 Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent Read More The post Ampio Pharmaceuticals CEO Mike Martino Issues Letter to Stockholders appeared first on Ampio Pharmaceuticals .

DURECT Corporation (NASDAQ:DRRX) with the stream of -3.86% also noticed, India Ampio Pharmaceuticals, Inc. (AMEX:AMPE) encountered a rapid change of -11.49% in the last hour of Tuesdays trading session. DURECT The post Traders cant blink on this: DURECT Corporation (NASDAQ:DRRX), Ampio Pharmaceuticals, Inc. (AMEX:AMPE) appeared first on Stocks Equity .

Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ampio (AMPE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Ampio Pharmaceuticals Inc. (AMEX:AMPE) price on Friday, December 10, rose 1.06% above its previous days close as an upside momentum from buyers pushed the stocks value to $0.99. A look at the stocks price movement, the close in the last trading session was $0.98, moving within a range at $0.98 and $1.05. The beta value Ampio Pharmaceuticals Inc. (AMPE) Is Worth Thinking About For The Coming Weeks Read More »

Zacks Investment Research upgraded shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning, Zacks.com reports. The brokerage currently has $1.25 price objective on the specialty pharmaceutical companys stock. According to Zacks, Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye []

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Dangling stocks: Nabriva Therapeutics plc (NASDAQ:NBRV -1.55%), Ampio Pharmaceuticals, Inc. (AMEX:AMPE -3.92%) appeared first on Stocks Equity .

Ampio Pharmaceuticals Inc. (AMEX:AMPE) price closed higher on Monday, December 06, jumping 5.15% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Zacks Investment Research downgraded shares of Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) from a buy rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include []

Price T Rowe Associates Inc. MD raised its position in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) by 13.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 128,758 shares of the specialty pharmaceutical companys stock after purchasing an additional 15,558 shares during the quarter. Price T []

California State Teachers Retirement System purchased a new position in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 263,125 shares of the specialty pharmaceutical companys stock, valued at approximately $439,000. California State Teachers Retirement System owned []

ENGLEWOOD, Colo., Nov. 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it will host a business update call with its chairman…